Pharmaceutical
Home » Central Nervous System Biomarkers Market

Central Nervous System Biomarkers Market

Central Nervous System Biomarkers Market By Type( Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers) By Application (Drug Discovery & Development, Personalized Medicine)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030
Report Book

Published Date: July 2023
Category: Pharmaceuticals
Report ID: 59004
Report Format: PDF
No of Pages: 190

Rating: Credence Reports

Key Highlights of the Report

The global central nervous system biomarkers market is segmented by type, application, end-user, and region. The safety biomarkers type holds the largest market share, while the validation biomarkers segment is projected to exhibit the highest growth rate. Drug discovery & development is the dominant application segment, and diagnostic labs are the leading end-user segment.

The global market for central nervous system biomarkers is driven by factors such as the increasing prevalence of neurological disorders, advancements in biomarker discovery technologies, and the growing demand for personalized medicine. However, the market faces challenges, including high development costs, stringent regulatory requirements, and the complex nature of central nervous system diseases.

Nonetheless, there are opportunities for global central nervous system biomarkers market growth, including developing novel biomarkers, advancements in imaging and molecular diagnostics, and rising investment in neuroscience research. Additionally, integrating artificial intelligence and machine learning technologies and expanding emerging markets offer further avenues for market expansion in the coming years.

Market Overview

The global central nervous system biomarkers market has witnessed steady growth in recent years and is expected to continue growing at a CAGR of 9.3% between 2023 and 2030. The market was valued at USD 4.2 billion in 2022 and is expected to reach USD 7.82 billion in 2030.

What Are The Main Drivers Of The Global Central Nervous System Biomarkers Market?

The growing prevalence of central nervous system disorders, emerging demands for early and accurate diagnosis of neurological conditions, advancements in biomarker technologies, and a growing emphasis on personalized medicine and targeted therapies for neurological diseases are the major drivers of the global central nervous system biomarkers market growth.

What Are The Major Challenges Faced By The Global Central Nervous System Biomarkers Market?

The major challenges faced by the global central nervous system biomarkers market include the complexity and heterogeneity of neurological disorders, the need for extensive validation and standardization of biomarker assays, regulatory hurdles in biomarker development and approval, and the high cost associated with biomarker research and development.

What Are The Growth Opportunities In The Global Central Nervous System Biomarkers Market?

The global central nervous system biomarkers market presents growth opportunities driven by advancements in technology for biomarker discovery and analysis, increasing research focus on personalized medicine and targeted therapies, rising demand for non-invasive diagnostic tools, and the potential application of biomarkers in early disease detection and monitoring. Besides, collaborations between academic institutions, pharmaceutical companies, diagnostic laboratories, and developing novel biomarker panels and multi-modal approaches contribute to the market’s growth prospects.

Central Nervous System Biomarkers Market

Executive Summary

Overview of the Global Central Nervous System Biomarkers Market

The global central nervous system (CNS) biomarkers market is experiencing significant growth due to the increasing prevalence of neurological disorders and the emerging demand for personalized medicine. Central nervous system biomarkers are measurable indicators that provide valuable insights into the diagnosis, prognosis, and treatment response of neurological conditions. These biomarkers can be proteins, genetic markers, imaging agents, or metabolites found in body fluids, tissues, or imaging scans. The market encompasses various products and services related to biomarker discovery, development, validation, and commercialization.

Market Definition

The central nervous system biomarkers market includes various biomarkers and associated products and services used to identify and assess neurological disorders. Biomarkers in this market can be diverse, including genetic, protein, imaging, and other markers. Diagnostic tests, imaging technologies, laboratory assays, and data analysis tools are all important in discovering, validating, and implementing central nervous system biomarkers. Key products and services in this market comprise biomarker kits, assay platforms, imaging systems, laboratory services, and data analytics solutions. The central nervous system biomarkers market drives advancements in understanding neurological disorders, facilitating personalized treatment approaches, and contributing to the development of innovative therapies.

Market Insights

  • The global demand for central nervous system biomarkers was valued at USD 4.2 Billion in 2022 and is expected to reach USD 7.82 Billion in 2030, growing at a CAGR of 9.3% between 2023 and 2030.
  • Safety biomarkers hold the largest market share by type, accounting for over 35% of the market value in 2022, while the validation biomarkers segment is expected to witness the fastest growth in the forecast period.
  • The drug discovery & development application segment dominates the market, with a substantial share of over 38% in 2022, driven by the need for efficient and targeted therapies for CNS disorders.
  • Clinics/hospitals are projected to experience the highest CAGR among end-users, while diagnostic labs currently lead the market share with over 40% in 2022.
  • North America emerged as the leading market in 2022, capturing more than 44% of the global revenue, attributed to advanced healthcare infrastructure, significant research activities, and a high prevalence of CNS disorders.
  • The Asia Pacific region presents significant growth potential due to increasing healthcare expenditure, awareness about CNS disorders, and expanding research initiatives.
  • Technological advancements in imaging techniques, molecular biology, and bioinformatics have facilitated identifying and validating novel biomarkers, enabling improved diagnosis, monitoring, and treatment of neurological conditions.

Segmentation by Type

  • Safety biomarkers dominate the market, accounting for over 35% of the market share in terms of value in 2022.
  • The validation biomarkers segment is expected to grow fastest during the projected period.
  • Efficacy biomarkers and other types also contribute to the demand for central nervous system biomarkers.

Segmentation by Application

  • The drug discovery & development segment governs the global demand for central nervous system biomarkers, holding a massive share of over 38% in 2022.
  • The personalized medicine segment contributes to the remaining demand for biomarkers in the central nervous system field.

Segmentation by End User

  • The clinics/hospitals segment will post the highest CAGR over the projected period.
  • Diagnostic labs currently lead the market share with over 40% in 2022.

Segmentation by Region

  • North America dominated the global central nervous system biomarkers market in 2022, accounting for over 44% of revenue share.
  • Europe is another prominent market for central nervous system biomarkers, contributing substantially to the overall global market share.
  • The Asia-Pacific region is experiencing rapid CAGR growth in the central nervous system biomarkers industry.
  • The rest of the World, including regions like the Middle East, Latin America, and Africa, is witnessing the rapid adoption of central nervous system biomarkers.

The global central nervous system biomarkers market is driven by the rise in the prevalence of neurological disorders, growing demand for personalized medicine and targeted therapies, advancements in biomarker discovery and validation techniques, and the rising emphasis on early disease diagnosis. However, the market faces challenges such as the high biomarker development and validation cost, stringent regulatory requirements, and the complexity of central nervous system diseases.

The United States is a key country in the global central nervous system biomarkers market. It has a highly developed healthcare infrastructure and a robust R&D ecosystem, making it a hub for biomarker discovery and clinical trials. The country has a high prevalence of central nervous system disorders and a large patient population, driving the demand for biomarkers. Besides, major pharmaceutical and biotechnology companies in the U.S. contribute to biomarker research and development advancements.

China is another major country in the global central nervous system biomarkers market. The country has a rapidly growing healthcare sector and a large population, providing a significant market opportunity. China has invested heavily in R&D, leading to biomarker discovery and diagnostics advancements. The rising prevalence of central nervous system disorders, such as Alzheimer’s and Parkinson’s, in China has created a need for effective biomarkers for early detection and monitoring. The government’s initiatives to promote precision medicine and personalized healthcare further support the growth of the biomarkers market in China.

Increasing Prevalence of Central Nervous System Disorders

The growing incidence of central nervous system disorders, such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, is a major driver of the global central nervous system biomarkers market. These disorders pose significant healthcare challenges, and the need for accurate diagnosis, prognosis, and monitoring drives the demand for biomarkers.

Advancements in Biomarker Discovery and Diagnostic Technologies

Rapid advancements in biomarker discovery techniques, including genomics, proteomics, and imaging technologies, have expanded the possibilities of identifying and validating biomarkers for central nervous system disorders. These advancements enable earlier and more accurate diagnoses, facilitate personalized medicine approaches, and support the development of targeted therapies.

Regulatory Challenges

The development and approval of biomarkers for clinical use face regulatory challenges due to the need for rigorous validation and standardization. Stringent regulatory requirements can pose barriers to the market entry of new biomarkers, prolonging the time to market and increasing development costs.

Personalized Medicine and Precision Healthcare

The shift towards personalized medicine and precision healthcare presents significant growth opportunities for the central nervous system biomarkers market. Biomarkers can enable tailored treatment approaches, assist in patient stratification for clinical trials, and facilitate precision medicine interventions for improved patient outcomes.

Rising Investments in Biomarker Research and Development

Increased investments by pharmaceutical companies, research organizations, and government bodies in biomarker research and development present opportunities for market growth. Collaborations, partnerships, and funding initiatives to advance biomarker discovery and validation are expected to propel innovation and accelerate the development of novel biomarkers for central nervous system disorders.

Competitive Landscape

Key Players

The global central nervous system biomarkers market is highly competitive and fragmented, with several key players operating in the industry. Some of the major players in the market and their market share are as follows:

These companies focus on R&D activities to develop innovative biomarkers for neurological disorders and establish strategic collaborations and partnerships with academic institutions and research organizations. Additionally, market players emphasize expanding their product portfolios by introducing new biomarker assays and diagnostic kits. Technological advancements, regulatory approvals, and the ability to provide accurate and reliable biomarker solutions further influence the competitive landscape. The market is expected to witness increased competition in the coming years as companies aim to capitalize on the growing demand for biomarkers in central nervous system disorders.

For example, Eisai Co. Ltd and Biogen Inc announced a presentation in November 2021 about investigating the use of plasma-based biomarkers in Phase 3 AHEAD 3-45 research of lecanemab (BAN2401), an experimental anti-amyloid beta (A) protofibril antibody for Alzheimer’s disease.

Likewise, Diadem confirmed the publication of clinical data demonstrating that its AlzoSure biomarker test can identify the course of Alzheimer’s disease years before symptoms appear in October 2021.

Summary of Key Findings

  • The increase in the prevalence of neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, is driving the demand for central nervous system biomarkers.
  • Market segmented by type, application, end-user, and region.
  • Biomarkers play a crucial role in early disease detection, accurate diagnosis, and monitoring of disease progression in central nervous system disorders.
  • Growing investment in R&D activities, particularly in genomics and proteomics, is contributing to expanding the central nervous system biomarkers market.
  • The adoption of precision medicine approaches and personalized treatment strategies is fueling the demand for biomarkers that can assist in patient stratification and targeted therapies.
  • Stringent regulatory requirements, ethical considerations, and the need for standardized protocols pose challenges to the market growth and widespread adoption of biomarkers.

Future Outlook

  • Market players actively engage in strategic collaborations, partnerships, and acquisitions to leverage complementary expertise, expand their product pipelines, and accelerate biomarker research and development efforts.
  • The exploration of non-invasive and easily accessible biomarkers, such as wearable devices and digital health technologies, holds promise for remote monitoring and early detection of central nervous system disorders.
  • The adoption of central nervous system biomarkers in clinical trials is gaining momentum, as they can serve as reliable indicators for evaluating treatment efficacy and safety, enabling faster drug development and regulatory approvals.

Segmentation

  • By Type
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Validation Biomarkers
    • Others
  • By Application
    • Drug Discovery & Development
    • Personalized Medicine
    • Others
  • By End User
    • Diagnostic Labs
    • Clinics/Hospitals
    • Research Centers
  • By Region
  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Data Modelling
1.3.2.1. Company Share Analysis Model
1.3.2.2. Revenue Based Modelling
1.3.3. Phase III – Primary Research
1.3.4. Research Limitations
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Central Nervous System Biomarkers Market
2.2. Global Central Nervous System Biomarkers Market, By Type
2.3. Global Central Nervous System Biomarkers Market, By End User
2.4. Global Central Nervous System Biomarkers Market, By Application
2.5. Global Central Nervous System Biomarkers Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Central Nervous System Biomarkers Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Type
3.5.2. End User
3.5.3. Application
3.5.4. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company market share of key players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Central Nervous System Biomarkers Market, By Type
7.1. Global Central Nervous System Biomarkers Market Overview, by Type
7.1.1. Global Central Nervous System Biomarkers Market Revenue Share, By Type, 2022 Vs 2030 (in %)
7.2. Safety Biomarkers
7.2.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)
7.3. Efficacy Biomarkers
7.3.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)
7.4. Validation Biomarkers
7.4.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)
7.5. Others
7.5.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)

8. Global Central Nervous System Biomarkers Market, By End User
8.1. Global Central Nervous System Biomarkers Market Overview, by End User
8.1.1. Global Central Nervous System Biomarkers Market, By End User, 2022 vs 2030 (in %)
8.2. Diagnostic Labs
8.2.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)
8.3. Clinics/Hospitals
8.3.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)
8.4. Research Centers
8.4.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)

9. Global Central Nervous System Biomarkers Market, by Application, 2017-2030 (US$ Bn)
9.1. Global Central Nervous System Biomarkers Market Overview, by Application
9.1.1. Global Central Nervous System Biomarkers Market, By Application, 2022 vs 2030 (in%)
9.2. Drug Discovery & Development
9.2.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)
9.3. Personalized Medicine
9.3.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)
9.4. Others
9.4.1. Global Central Nervous System Biomarkers Market, By Region, 2017-2030 (US$ Bn)

10. Global Central Nervous System Biomarkers Market, By Region
10.1. Global Central Nervous System Biomarkers Market Overview, by Region
10.1.1. Global Central Nervous System Biomarkers Market, By Region, 2022 vs 2030 (in%)
10.2. Type
10.2.1. Global Central Nervous System Biomarkers Market, By Type, 2017-2030 (US$ Bn)
10.3. End User
10.3.1. Global Central Nervous System Biomarkers Market, By End User, 2017-2030 (US$ Bn)
10.4. Application
10.4.1. Global Central Nervous System Biomarkers Market, By Application, 2017-2030 (US$ Bn)

11. North America Central Nervous System Biomarkers Market Analysis
11.1. North America Central Nervous System Biomarkers Market, by Type, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. North America Central Nervous System Biomarkers Market, by End User, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. North America Central Nervous System Biomarkers Market, by Application, 2017-2030(US$ Bn)
11.3.1. Overview
11.3.2. SRC Analysis
11.4. North America Central Nervous System Biomarkers Market, by Country, 2017-2030 (US$ Bn)
11.4.1. North America Central Nervous System Biomarkers Market, by Country, 2022 Vs 2030 (in%)
11.4.2. U.S.
11.4.2.1. U.S. Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.4.2.2. U.S. Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
11.4.2.3. U.S. Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
11.4.2.4. U.S. Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
11.4.3. Canada
11.4.3.1. Canada Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.4.3.2. Canada Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
11.4.3.3. Canada Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
11.4.3.4. Canada Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
11.4.4. Mexico
11.4.4.1. Mexico Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.4.4.2. Mexico Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
11.4.4.3. Mexico Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
11.4.4.4. Mexico Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)

12. Europe Central Nervous System Biomarkers Market Analysis
12.1. Europe Central Nervous System Biomarkers Market, by Type, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Europe Central Nervous System Biomarkers Market, by End User, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Europe Central Nervous System Biomarkers Market, by Application, 2017-2030(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Europe Central Nervous System Biomarkers Market, by Country, 2017-2030 (US$ Bn)
12.4.1. Europe Central Nervous System Biomarkers Market, by Country, 2022 Vs 2030 (in%)
12.4.2. Germany
12.4.2.1. Germany Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.2.2. Germany Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
12.4.2.3. Germany Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
12.4.2.4. Germany Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
12.4.3. France
12.4.3.1. France Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.3.2. France Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
12.4.3.3. France Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
12.4.3.4. France Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
12.4.4. UK
12.4.4.1. UK Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.4.2. UK Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
12.4.4.3. UK Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
12.4.4.4. UK Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
12.4.5. Italy
12.4.5.1. Italy Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.5.2. Italy Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
12.4.5.3. Italy Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
12.4.5.4. Italy Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
12.4.6. Spain
12.4.6.1. Spain Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.6.2. Spain Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
12.4.6.3. Spain Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
12.4.6.4. Spain Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
12.4.7. Rest of Europe
12.4.7.1. Rest of Europe Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.4.7.2. Rest of Europe Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
12.4.7.3. Rest of Europe Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
12.4.7.4. Rest of Europe Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)

13. Asia Pacific Central Nervous System Biomarkers Market Analysis
13.1. Asia Pacific Central Nervous System Biomarkers Market, by Type, 2017-2030(US$ Bn)
13.1.1. Overview
13.1.2. SRC Analysis
13.2. Asia Pacific Central Nervous System Biomarkers Market, by End User, 2017-2030(US$ Bn)
13.2.1. Overview
13.2.2. SRC Analysis
13.3. Asia Pacific Central Nervous System Biomarkers Market, by Application, 2017-2030(US$ Bn)
13.3.1. Overview
13.3.2. SRC Analysis
13.4. Asia Pacific Central Nervous System Biomarkers Market, by Country, 2017-2030 (US$ Bn)
13.4.1. Asia Pacific Central Nervous System Biomarkers Market, by Country, 2022 Vs 2030 (in%)
13.4.2. China
13.4.2.1. China Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.2.2. China Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
13.4.2.3. China Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
13.4.2.4. China Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
13.4.3. Japan
13.4.3.1. Japan Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.3.2. Japan Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
13.4.3.3. Japan Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
13.4.3.4. Japan Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
13.4.4. India
13.4.4.1. India Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.4.2. India Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
13.4.4.3. India Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
13.4.4.4. India Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
13.4.5. South Korea
13.4.5.1. South Korea Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.5.2. South Korea Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
13.4.5.3. South Korea Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
13.4.5.4. South Korea Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
13.4.6. South-East Asia
13.4.6.1. South-East Asia Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.6.2. South-East Asia Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
13.4.6.3. South-East Asia Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
13.4.6.4. South-East Asia Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
13.4.7. Rest of Asia Pacific
13.4.7.1. Rest of Asia Pacific Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
13.4.7.2. Rest of Asia Pacific Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
13.4.7.3. Rest of Asia Pacific Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
13.4.7.4. Rest of Asia Pacific Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)

14. Latin America Central Nervous System Biomarkers Market Analysis
14.1. Latin America Central Nervous System Biomarkers Market, by Type, 2017-2030(US$ Bn)
14.1.1. Overview
14.1.2. SRC Analysis
14.2. Latin America Central Nervous System Biomarkers Market, by End User, 2017-2030(US$ Bn)
14.2.1. Overview
14.2.2. SRC Analysis
14.3. Latin America Central Nervous System Biomarkers Market, by Application, 2017-2030(US$ Bn)
14.3.1. Overview
14.3.2. SRC Analysis
14.4. Latin America Central Nervous System Biomarkers Market, by Country, 2017-2030 (US$ Bn)
14.4.1. Latin America Central Nervous System Biomarkers Market, by Country, 2022 Vs 2030 (in%)
14.4.2. Brazil
14.4.2.1. Brazil Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.4.2.2. Brazil Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
14.4.2.3. Brazil Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
14.4.2.4. Brazil Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
14.4.3. Argentina
14.4.3.1. Argentina Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.4.3.2. Argentina Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
14.4.3.3. Argentina Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
14.4.3.4. Argentina Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
14.4.4. Rest of Latin America
14.4.4.1. Rest of Latin America Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
14.4.4.2. Rest of Latin America Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
14.4.4.3. Rest of Latin America Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
14.4.4.4. Rest of Latin America Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)

15. Middle East and Africa Central Nervous System Biomarkers Market Analysis
15.1. Middle East and Africa Central Nervous System Biomarkers Market, by Type, 2017-2030(US$ Bn)
15.1.1. Overview
15.1.2. SRC Analysis
15.2. Middle East and Africa Central Nervous System Biomarkers Market, by End User, 2017-2030(US$ Bn)
15.2.1. Overview
15.2.2. SRC Analysis
15.3. Middle East and Africa Central Nervous System Biomarkers Market, by Application, 2017-2030(US$ Bn)
15.3.1. Overview
15.3.2. SRC Analysis
15.4. Middle East and Africa Central Nervous System Biomarkers Market, by Country, 2017-2030 (US$ Bn)
15.4.1. Middle East and Africa Central Nervous System Biomarkers Market, by Country, 2022 Vs 2030 (in%)
15.4.2. GCC Countries
15.4.2.1. GCC Countries Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.4.2.2. GCC Countries Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
15.4.2.3. GCC Countries Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
15.4.2.4. GCC Countries Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
15.4.3. South Africa
15.4.3.1. South Africa Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.4.3.2. South Africa Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
15.4.3.3. South Africa Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
15.4.3.4. South Africa Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)
15.4.4. Rest of Middle East and Africa
15.4.4.1. Rest of Middle East and Africa Central Nervous System Biomarkers Market Estimates and Forecast, 2017-2030 (US$ Bn)
15.4.4.2. Rest of Middle East and Africa Central Nervous System Biomarkers, By Type, 2017-2030 (US$ Bn)
15.4.4.3. Rest of Middle East and Africa Central Nervous System Biomarkers, By End User, 2017-2030 (US$ Bn)
15.4.4.4. Rest of Middle East and Africa Central Nervous System Biomarkers, By Application, 2017-2030 (US$ Bn)

16. Company Profiles
16.1. Acumen Pharmaceuticals Inc
16.1.1. Company Overview
16.1.2. Products/Services Portfolio
16.1.3. Geographical Presence
16.1.4. Financial Summary
16.1.4.1. Market Revenue and Net Profit (2019-2022)
16.1.4.2. Business Segment Revenue Analysis
16.1.4.3. Geographical Revenue Analysis
16.2. Alseres Pharmaceuticals Inc
16.3. Avacta Life Sciences Limited
16.4. bioMérieux (Banyan Biomarkers Inc)
16.5. Bio-Rad Laboratories Inc
16.6. G-Biosciences
16.7. Merck KGaA
16.8. Thermo Fisher Scientific Inc
16.9. Eli Lilly & Company (Avid Radiopharmaceuticals Inc)
16.10. Proteome Sciences PLC
16.11. Enzo Biochem Inc
16.12. H.U. Group Holdings
16.13. Acro Biosystems

List of Figures
FIG. 1 Global Central Nervous System Biomarkers Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Central Nervous System Biomarkers Market Segmentation
FIG. 4 Global Central Nervous System Biomarkers Market, by Type, 2022 (US$ Bn)
FIG. 5 Global Central Nervous System Biomarkers Market, by End User, 2022 (US$ Bn)
FIG. 6 Global Central Nervous System Biomarkers Market, by Application, 2022 (US$ Bn)
FIG. 7 Global Central Nervous System Biomarkers Market, by Geography, 2022 (US$ Bn)
FIG. 8 Attractive Investment Proposition, by Type, 2022
FIG. 9 Attractive Investment Proposition, by End User, 2022
FIG. 10 Attractive Investment Proposition, by Application, 2022
FIG. 11 Attractive Investment Proposition, by Geography, 2022
FIG. 12 Global Market Share Analysis of Key Central Nervous System Biomarkers Market Manufacturers, 2022
FIG. 13 Global Market Positioning of Key Central Nervous System Biomarkers Market Manufacturers, 2022
FIG. 14 Global Central Nervous System Biomarkers Market Value Contribution, By Type, 2022 & 2030 (Value %)
FIG. 15 Global Central Nervous System Biomarkers Market, by Safety Biomarkers, Value, 2017-2030 (US$ Bn)
FIG. 16 Global Central Nervous System Biomarkers Market, by Efficacy Biomarkers, Value, 2017-2030 (US$ Bn)
FIG. 17 Global Central Nervous System Biomarkers Market, by Validation Biomarkers, Value, 2017-2030 (US$ Bn)
FIG. 18 Global Central Nervous System Biomarkers Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 19 Global Central Nervous System Biomarkers Market Value Contribution, By End User, 2022 & 2030 (Value %)
FIG. 20 Global Central Nervous System Biomarkers Market, by Diagnostic Labs, Value, 2017-2030 (US$ Bn)
FIG. 21 Global Central Nervous System Biomarkers Market, by Clinics/Hospitals, 2017-2030 (US$ Bn)
FIG. 22 Global Central Nervous System Biomarkers Market, by Research Centers, 2017-2030 (US$ Bn)
FIG. 23 Global Central Nervous System Biomarkers Market Value Contribution, By Application, 2022 & 2030 (Value %)
FIG. 24 Global Central Nervous System Biomarkers Market, by Drug Discovery & Development, Value, 2017-2030 (US$ Bn)
FIG. 25 Global Central Nervous System Biomarkers Market, by Personalized Medicine, 2017-2030 (US$ Bn)
FIG. 26 Global Central Nervous System Biomarkers Market, by Others, 2017-2030 (US$ Bn)
FIG. 27 North America Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 28 U.S. Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 29 Canada Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 30 Europe Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 31 Germany Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 32 France Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 33 U.K. Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 34 Italy Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 35 Spain Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 36 Rest of Europe Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 37 Asia Pacific Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 38 China Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 39 Japan Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 40 India Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 41 South Korea Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 42 South-East Asia Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 43 Rest of Asia Pacific Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 44 Latin America Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 45 Brazil Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 46 Mexico Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 47 Rest of Latin America Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 48 Middle East & Africa Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 49 GCC Countries Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 50 South Africa Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)
FIG. 51 Rest of Middle East and Africa Central Nervous System Biomarkers Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Central Nervous System Biomarkers Market
TABLE 2 Global Central Nervous System Biomarkers Market: Market Drivers Impact Analysis
TABLE 3 Global Central Nervous System Biomarkers Market: Market Restraints Impact Analysis
TABLE 4 Global Central Nervous System Biomarkers Market, by Competitive Benchmarking, 2022
TABLE 5 Global Central Nervous System Biomarkers Market, by Geographical Presence Analysis, 2022
TABLE 6 Global Central Nervous System Biomarkers Market, by Key Strategies Analysis, 2022
TABLE 7 Global Central Nervous System Biomarkers Market, by Safety Biomarkers, By Region, 2017-2022 (US$ Bn)
TABLE 8 Global Central Nervous System Biomarkers Market, by Safety Biomarkers, By Region, 2023-2030 (US$ Bn)
TABLE 9 Global Central Nervous System Biomarkers Market, by Efficacy Biomarkers, By Region, 2017-2022 (US$ Bn)
TABLE 10 Global Central Nervous System Biomarkers Market, by Efficacy Biomarkers, By Region, 2023-2030 (US$ Bn)
TABLE 11 Global Central Nervous System Biomarkers Market, by Validation Biomarkers, By Region, 2017-2022 (US$ Bn)
TABLE 12 Global Central Nervous System Biomarkers Market, by Validation Biomarkers, By Region, 2023-2030 (US$ Bn)
TABLE 13 Global Central Nervous System Biomarkers Market, by Diagnostic Labs, By Region, 2017-2022 (US$ Bn)
TABLE 14 Global Central Nervous System Biomarkers Market, by Diagnostic Labs, By Region, 2023-2030 (US$ Bn)
TABLE 15 Global Central Nervous System Biomarkers Market, by Clinics/Hospitals, By Region, 2017-2022 (US$ Bn)
TABLE 16 Global Central Nervous System Biomarkers Market, by Clinics/Hospitals, By Region, 2023-2030 (US$ Bn)
TABLE 17 Global Central Nervous System Biomarkers Market, by Research Centers, By Region, 2017-2022 (US$ Bn)
TABLE 18 Global Central Nervous System Biomarkers Market, by Research Centers, By Region, 2023-2030 (US$ Bn)
TABLE 19 Global Central Nervous System Biomarkers Market, by Drug Discovery & Development, By Region, 2017-2022 (US$ Bn)
TABLE 20 Global Central Nervous System Biomarkers Market, by Drug Discovery & Development, By Region, 2023-2030 (US$ Bn)
TABLE 21 Global Central Nervous System Biomarkers Market, by Personalized Medicine, By Region, 2017-2022 (US$ Bn)
TABLE 22 Global Central Nervous System Biomarkers Market, by Personalized Medicine, By Region, 2023-2030 (US$ Bn)
TABLE 23 Global Central Nervous System Biomarkers Market, by Others, By Region, 2017-2022 (US$ Bn)
TABLE 24 Global Central Nervous System Biomarkers Market, by Others, By Region, 2023-2030 (US$ Bn)
TABLE 25 Global Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 26 Global Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 27 Global Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 28 Global Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 29 Global Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 30 Global Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 31 Global Central Nervous System Biomarkers Market, by Region, 2017-2022 (US$ Bn)
TABLE 32 Global Central Nervous System Biomarkers Market, by Region, 2023-2030 (US$ Bn)
TABLE 33 North America Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 34 North America Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 35 North America Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 36 North America Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 37 North America Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 38 North America Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 39 North America Central Nervous System Biomarkers Market, by Country, 2017-2022 (US$ Bn)
TABLE 40 North America Central Nervous System Biomarkers Market, by Country, 2023-2030 (US$ Bn)
TABLE 41 United States Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 42 United States Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 43 United States Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 44 United States Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 45 United States Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 46 United States Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 47 Canada Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 48 Canada Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 49 Canada Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 50 Canada Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 51 Canada Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 52 Canada Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 53 Mexico Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 54 Mexico Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 55 Mexico Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 56 Mexico Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 57 Mexico Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 58 Mexico Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 59 Europe Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 60 Europe Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 61 Europe Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 62 Europe Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 63 Europe Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 64 Europe Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 65 Europe Central Nervous System Biomarkers Market, by Country, 2017-2022 (US$ Bn)
TABLE 66 Europe Central Nervous System Biomarkers Market, by Country, 2023-2030 (US$ Bn)
TABLE 67 Germany Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 68 Germany Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 69 Germany Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 70 Germany Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 71 Germany Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 72 Germany Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 73 France Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 74 France Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 75 France Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 76 France Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 77 France Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 78 France Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 79 United Kingdom Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 80 United Kingdom Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 81 United Kingdom Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 82 United Kingdom Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 83 United Kingdom Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 84 United Kingdom Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 85 Italy Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 86 Italy Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 87 Italy Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 88 Italy Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 89 Italy Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 90 Italy Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 91 Spain Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 92 Spain Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 93 Spain Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 94 Spain Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 95 Spain Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 96 Spain Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 97 Rest of Europe Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 98 Rest of Europe Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 99 Rest of Europe Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 100 Rest of Europe Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 101 Rest of Europe Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 102 Rest of Europe Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 103 Asia Pacific Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 104 Asia Pacific Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 105 Asia Pacific Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 106 Asia Pacific Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 107 Asia Pacific Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 108 Asia Pacific Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 109 China Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 110 China Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 111 China Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 112 China Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 113 China Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 114 China Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 115 Japan Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 116 Japan Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 117 Japan Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 118 Japan Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 119 Japan Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 120 Japan Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 121 India Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 122 India Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 123 India Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 124 India Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 125 India Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 126 India Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 127 South Korea Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 128 South Korea Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 129 South Korea Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 130 South Korea Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 131 South Korea Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 132 South Korea Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 133 South-East Asia Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 134 South-East Asia Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 135 South-East Asia Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 136 South-East Asia Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 137 South-East Asia Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 138 South-East Asia Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 139 Rest of Asia Pacific Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 140 Rest of Asia Pacific Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 141 Rest of Asia Pacific Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 142 Rest of Asia Pacific Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 143 Rest of Asia Pacific Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 144 Rest of Asia Pacific Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 145 Latin America Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 146 Latin America Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 147 Latin America Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 148 Latin America Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 149 Latin America Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 150 Latin America Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 151 Brazil Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 152 Brazil Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 153 Brazil Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 154 Brazil Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 155 Brazil Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 156 Brazil Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 157 Argentina Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 158 Argentina Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 159 Argentina Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 160 Argentina Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 161 Argentina Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 162 Argentina Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 163 Rest of Latin America Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 164 Rest of Latin America Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 165 Rest of Latin America Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 166 Rest of Latin America Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 167 Rest of Latin America Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 168 Rest of Latin America Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 169 Middle East and Africa Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 170 Middle East and Africa Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 171 Middle East and Africa Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 172 Middle East and Africa Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 173 Middle East and Africa Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 174 Middle East and Africa Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 175 GCC Countries Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 176 GCC Countries Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 177 GCC Countries Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 178 GCC Countries Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 179 GCC Countries Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 180 GCC Countries Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 181 South Africa Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 182 South Africa Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 183 South Africa Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 184 South Africa Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 185 South Africa Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 186 South Africa Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)
TABLE 187 Rest of Middle East and Africa Central Nervous System Biomarkers Market, by Type, 2017-2022 (US$ Bn)
TABLE 188 Rest of Middle East and Africa Central Nervous System Biomarkers Market, by Type, 2023-2030 (US$ Bn)
TABLE 189 Rest of Middle East and Africa Central Nervous System Biomarkers Market, by End User, 2017-2022 (US$ Bn)
TABLE 190 Rest of Middle East and Africa Central Nervous System Biomarkers Market, by End User, 2023-2030 (US$ Bn)
TABLE 191 Rest of Middle East and Africa Central Nervous System Biomarkers Market, by Application, 2017-2022 (US$ Bn)
TABLE 192 Rest of Middle East and Africa Central Nervous System Biomarkers Market, by Application, 2023-2030 (US$ Bn)

Frequently Asked Questions

What is the current size of the global central nervous system biomarkers market?

The global central nervous system biomarkers market was valued at USD 4.2 Billion in 2022.

What is the expected growth rate of the central nervous system biomarkers market between 2023 and 2030?

The central nervous system biomarkers market is expected to grow at a CAGR of 9.3% between 2023 and 2030, reaching USD 7.82 Billion in 2030.

Which segment is leading the market share in terms of type?

Safety biomarkers are the leading segment by type, holding over 35% share in terms of value in 2022.

Which application segment governs the global demand for central nervous system biomarkers?

The drug discovery & development segment governs the global demand for central nervous system biomarkers, holding a massive share of over 38% in 2022.

Which end-user segment will post the highest CAGR in the forecast period?

The clinics/hospitals segment will post the highest CAGR in the projected period.

Which region is fueling the growth of the central nervous system biomarkers industry?

Asia Pacific is fueling the rapid growth of the central nervous system biomarkers industry, with an over one-third share in 2022.

Who are the major players in the global central nervous system biomarkers market?

The top players include Acumen Pharmaceuticals Inc, Bio-Rad Laboratories Inc, Merck KGaA, and Proteome Sciences PLC. Other major players include Thermo Fisher Scientific Inc, Enzo Biochem Inc, Acro Biosystems, and Eli Lilly & Company.

What are the major market drivers of the central nervous system biomarkers industry?

The major market drivers are the increasing prevalence of neurological disorders, growing demand for personalized medicine, advancements in biomarker discovery techniques, and the rising focus on early disease diagnosis.

What are the major market restraints of the central nervous system biomarkers industry?

The major market restraints are the high biomarker development and validation cost, stringent regulatory requirements, and the complexity of central nervous system diseases.

What are the major market opportunities in the central nervous system biomarkers industry?

The major market opportunities in the central nervous system biomarkers industry include the development of novel biomarkers for various neurological conditions, increasing research and development activities, and the potential for collaborations and partnerships for biomarker discovery and validation.

Healthcare

Trientine Hydrochloride Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 58081
Report Format: PDF
No of Pages: 247

Pharmaceutical

Pharmaceutical Chemicals Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 62118
Report Format: PDF
No of Pages: 247

Pharmaceutical

Wilson’s Disease Drugs Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 58947
Report Format: PDF
No of Pages: 190

Healthcare

Stretch Marks Treatment Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62116
Report Format: PDF
No of Pages: 221

Pharmaceutical

Fetal Bovine Serum Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 62115
Report Format: PDF
No of Pages: 238

Healthcare

Cirrhosis Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62114
Report Format: PDF
No of Pages: 229

Pharmaceutical

Congenital Hyperinsulinism Treatment Market

Published Date: Sept 2023
Category: Pharmaceuticals
Report ID: 62113
Report Format: PDF
No of Pages: 219

Healthcare

Cryptococcal Meningitis Treatment Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62112
Report Format: PDF
No of Pages: 237

Healthcare

Dermatology Endoscopy devices Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62111
Report Format: PDF
No of Pages: 237

Healthcare

Cementless Total Knee Arthroplasty Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62110
Report Format: PDF
No of Pages: 228

Healthcare

Cell & Gene Therapy Clinical Trials Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 62109
Report Format: PDF
No of Pages: 228

HealthCare

Self-sampling Blood Collection and Storage Device Market

Published Date: Sept 2023
Category: Healthcare
Report ID: 61352
Report Format: PDF
No of Pages: 234

Download Sample Report


Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
WhatsApp Now